Reply to Hall J: “Use of the Fluocinolone Acetonide Intravitreal Implant for the Treatment of Noninfectious Posterior Uveitis: 3-Year Results of a Randomized Clinical Trial in a Predominantly Asian Population” by Baldo Scassellati Sforzolini
LETTER TO THE EDITOR
Reply to Hall J: ‘‘Use of the Fluocinolone Acetonide
Intravitreal Implant for the Treatment of Noninfectious
Posterior Uveitis: 3-Year Results of a Randomized
Clinical Trial in a Predominantly Asian Population’’
Virender S. Sangwan, P. Andrew Pearson, Hemanth Paul,
Timothy L. Comstock
Baldo Scassellati Sforzolini
To view enhanced content go to www.ophthalmology-open.com
Received: March 2, 2015 / Published online: March 21, 2015
 The Author(s) 2015. This article is published with open access at Springerlink.com
I read with interest Dr. Hall’s letter. While the
article titled ‘‘Use of the Fluocinolone Acetonide
Intravitreal Implant for the Treatment of
Noninfectious Posterior Uveitis (NIPU): 3-Year
Results of a Randomized Clinical Trial in a
Predominantly Asian Population’’ [1] clearly
identified Retisert (fluocinolone acetonide
intravitreal implant) 0.59 mg as the marketed
product used in the study, we appreciate Dr.
Hall’s concern that there may be some potential
confusion regarding the features of Retisert
compared with those of Iluvien (fluocinolone
acetonide intravitreal implant) 0.19 mg, as they
both contain fluocinolone acetonide as the
active ingredient, and we are in support of a
letter outlining their differences [2].
However, we disagree with the promotional
implication that Iluvien is an ‘‘improvement’’
over Retisert as there are no head-to-head clinical
trials comparing these two products to merit that
claim. Indeed, in addition to the approval for
treatment of chronic non-infectious posterior
uveitis, clinical studies have shown Retisert to be
effective in reducing diabetic macular edema
(DME) and improving visual acuity in patients
with DME [3]. Retisert has also shown efficacy in
the management of macular edema secondary to
retinal vein occlusion in small studies [4, 5].
However, as Dr. Hall correctly stated, Retisert is
not approved either in the US or in Europe for
these latter indications.
Baldo Scassellati Sforzolini, MD, PhD, MBA
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